t e c h n i c a l r e p o r t s
Detection of minor, genetically distinct subpopulations within tumors is a key challenge in cancer genomics. Here we report STAR-FISH (specific-to-allele PCR-FISH), a novel method for the combined detection of single-nucleotide and copy number alterations in single cells in intact archived tissues.
Using this method, we assessed the clinical impact of changes in the frequency and topology of PIK3CA mutation and HER2 (ERBB2) amplification within HER2-positive breast cancer during neoadjuvant therapy. We found that these two genetic events are not always present in the same cells. Chemotherapy selects for PIK3CA-mutant cells, a minor subpopulation in nearly all treatment-naive samples, and modulates genetic diversity within tumors. Treatment-associated changes in the spatial distribution of cellular genetic diversity correlated with poor long-term outcome following adjuvant therapy with trastuzumab. Our findings support the use of in situ single cell-based methods in cancer genomics and imply that chemotherapy before HER2-targeted therapy may promote treatment resistance.
Cancer is a genetic disease, and the identification of somatic genetic alterations in tumors thus has been the focus of clinical oncology. Cancer genome sequencing studies have traditionally been performed on bulk tumor samples, limiting their ability to detect minor subclones, which commonly drive therapy resistance 1, 2 . Sequencing of bulk tumor samples also cannot accurately predict which mutations are present in the same or in different cells. Sequencing of single cancer cells overcomes these limitations 3, 4 but is currently still laborious, expensive and prone to error as a result of the inefficiencies of whole-genome amplification; it is thus not yet suitable for the analysis of large patient cohorts. We have developed a novel methodology, termed STAR-FISH, based on the combination of in situ PCR [5] [6] [7] and FISH [8] [9] [10] to enable the simultaneous detection of point mutations and copy number variations at the single-cell level in intact formalinfixed, paraffin-embedded tissue samples.
We designed STAR-FISH for several commonly mutated genes in breast cancer, focusing on clinically relevant mutational hotspots. PIK3CA is one of the most commonly mutated genes in breast cancer 11 . Mutations in PIK3CA 12 , predominantly occurring at two hotspots (p.Glu542Lys (c.1624G>A) and p.His1047Arg (c.3140A>G)), are present in about 20% of all breast tumors and in up to 40% of cancers in the HER2-positive subtype. The phosphoinositide 3-kinase (PI3K)-AKT pathway has been identified as a major determinant of resistance to trastuzumab, an antibody targeting HER2 (also known as ERBB2) [13] [14] [15] [16] [17] [18] [19] , implying that PIK3CA mutation might be used as a predictor of resistance. However, the substantial heterogeneity for PIK3CA mutation, both within different regions of the same tumor and between different lesions in the same patient 20, 21 , make its accurate detection challenging. We applied STAR-FISH to assess changes in intratumoral cellular heterogeneity for HER2 amplification and the PIK3CA mutation encoding p.His1047Arg in a cohort of patients with HER2-positive breast cancer subjected to neoadjuvant chemotherapy followed by adjuvant therapy with trastuzumab and correlated these changes with long-term clinical outcome.
RESULTS

STAR-FISH development and validation
The first step of STAR-FISH is an in situ PCR reaction using mismatched primers designed to specifically amplify mutant and wildtype alleles (Fig. 1a, Supplementary Fig. 1a , Supplementary Table 1 In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer and Supplementary Note). The primers contain a 5′ overhang constituting a unique sequence not found in the human genome, which serves as a priming site in the second round of PCR. The use of a few amplification cycles in the first round of PCR and 30 amplification cycles in the second round of PCR ensures proper amplification of the product with high specificity. PCR products are visualized by hybridization with fluorescently labeled probe complementary to the 5′ overhang (Fig. 1a) . The specificity of the primers for the PIK3CA mutation encoding p.His1047Arg was first evaluated by PCR using genomic DNA isolated from human breast cancer cell lines with known PIK3CA mutation status (Fig. 1b) . The sensitivity of the assay was tested by performing PCR on defined mixtures of DNA from the MDA-MB-231 (PIK3CA wild type) and SUM-185PE (homozygous for the PIK3CA mutation encoding p.His1047Arg) cell lines ( Supplementary Figs. 1b and 2) . Primers for the second round of PCR were tested in the same manner (data not shown). We also developed PCR assays for two other commonly occurring mutations in breast cancer, PIK3CA mutation encoding p.Glu542Lys and TP53 mutation encoding p.Arg175His (Supplementary Fig. 1c,d) .
Next, we performed in situ PCR on formalin-fixed, paraffin-embedded tissue slides of xenografts derived from the MDA-MB-231 and T-47D breast cancer cell lines in mice ( Fig. 1c and Supplementary Fig. 1e ) followed by testing of primary human breast tumors with known status for the PIK3CA mutation encoding p.His1047Arg (Fig. 1d) . Signal for wild-type and mutant PIK3CA was robustly detected in cancer cells, whereas only wild-type signal was visible in surrounding stromal cells (Fig. 1d) . The false discovery rate (FDR) for PIK3CA mutation detection was equal to 1 in 976 cells (FDR = 0.001), on the basis of analysis of xenografts derived from the MDA-MB-231 cell line (PIK3CA wild type). No signal was detected when the polymerase was omitted in the first round of PCR, confirming the specificity of the in situ PCR step (Fig. 1d) . Similarly, we performed in situ PCR for Figure 1 Outline of the STAR-FISH method and its validation. (a) Schematic of the STAR-FISH protocol performed on a cell heterozygous for a mutation. In steps 1 and 2, in situ PCR with a mixture of primers to the wild-type (WT; green) and mutant (MUT; red) gene is performed. Red and green dots represent the mutation site. In step 3, hybridization of fluorescently labeled probes specific for the wild-type and mutant PCR products is combined with hybridization of BAC (magenta) and CEP (blue) probes for the detection of genomic copy number variation. (b) PCR to test the specificity of the primers for the PIK3CA His1047 codon using genomic DNA from breast cancer cell lines with known mutation status. MDA-MB-231, PIK3CA wild type; T-47D, heterozygous for the PIK3CA mutation encoding p.His1047Arg; SUM-185PE, homozygous for the PIK3CA mutation encoding p.His1047Arg. (c) In situ PCR testing the specificity of the primers for wild-type and mutant (p.His1047Arg) PIK3CA on T-47D breast cancer cell line xenografts. Top, only primers to the mutant allele were used in the first round of PCR, and both primer sets were used in the second round of PCR. Bottom, primers to both the wild-type and mutant alleles were used in both rounds of PCR. 
the PIK3CA mutation encoding p.Glu542Lys and the TP53 mutation encoding p.Arg175His on BT-483 cells in HistoGel and xenografts derived from AU565 cells, respectively, which are known to contain these mutations ( Supplementary Fig. 1f,g ).
To validate the sensitivity and specificity of the PIK3CA in situ PCR, we compared it to three independent methods: FACS, immunofluorescence and mass spectrometry 22 . For the comparisons with FACS and immunofluorescence, we used xenografts derived from defined mixtures of wild-type and mutant cell lines expressing fluorescent tags. The mutant cell fraction determined by STAR-FISH was in accordance with the FACS and immunofluorescence results, and the variance between replicates was not significantly different between the various methods ( Supplementary Fig. 3a-d ). For comparison with mass spectrometry, we performed in situ PCR for the PIK3CA mutation encoding p.His1047Arg on a cohort of breast tumors previously genotyped for this mutation by Sequenom MassARRAY 23, 24 . We observed a strong correlation (linear regression y = 1.013x, P < 0.0001; R 2 = 0.9037, P < 0.0001) between the two methods ( Supplementary  Fig. 4a-c) . Interestingly, even in samples where MassARRAY did not detect any mutant PIK3CA alleles, with STAR-FISH, we identified rare mutant cells below a frequency of 8%.
Lastly, we combined in situ PCR for the PIK3CA mutation encoding p.His1047Arg with FISH for a chromosomal region commonly gained in breast cancer and validated this method on a xenograft derived from the T-47D cell line, which is heterozygous for the PIK3CA mutation encoding p.His1047Arg and has an amplification at 11q13 (Fig. 1e) . We were able to detect clear signals for 11q13 amplification and both wild-type and mutant PIK3CA alleles in individual cancer cells. These results confirmed the high specificity and sensitivity of the STAR-FISH assay for the in situ detection of single-nucleotide mutations in combination with genomic copy number variation.
STAR-FISH analysis of HER2-positive breast tumor samples
We applied STAR-FISH for the analysis of PIK3CA mutation encoding p.His1047Arg and HER2 amplification status in a cohort of 22 patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy followed by adjuvant treatment with trastuzumab ( Supplementary Fig. 5 and Supplementary Table 2) . For each patient, we analyzed a treatment-naive biopsy sample and surgical excision of the residual tumor after neoadjuvant treatment. In each tissue sample, we evaluated 3-5 distinct areas of the tumor to account for regional heterogeneity. Using STAR-FISH, we quantified copy numbers for HER2 and chromosome 17 centromeric (CEP17) probes and PIK3CA wild-type and mutant signal in individual nuclei (on average, 289 nuclei per area; Fig. 2a,b) . Cells with nuclei having <200 pixels in the images were excluded as they likely correspond to infiltrating leukocytes. HER2 amplification was defined using HER2/CEP17 ratio ≥2.0 as the cutoff 25 . To facilitate further statistical and intratumoral diversity analyses based on these singlecell measurements, each cell with evaluable signal was assigned to one of the following categories: WT, a cell with wild-type PIK3CA signal and no HER2 amplification; WT + AMP, a cell with wild-type PIK3CA signal and HER2 amplification; MUT, a cell with mutant PIK3CA signal and no HER2 amplification; MUT + AMP, a cell with mutant PIK3CA signal and HER2 amplification; AMP, a cell with no PIK3CA signal and HER2 amplification ( Fig. 2c and Supplementary Table 3) . A subset of cells with no detectable signal for any of the four probes analyzed (NA) and cells with no PIK3CA signal and no HER2 amplification (HER2noAmp) were excluded from further analyses, as these cells likely represent non-specific technical outliers ( Supplementary  Fig. 6 , Supplementary Table 4 and Supplementary Note).
Analyzing the frequency of these cell types in all cases demonstrated that the majority of the untreated tumors were composed of cells with HER2 amplification and wild-type PIK3CA, with very small fractions of cells with mutant PIK3CA (Fig. 3a and Supplementary Figs. 7 and 8a). In contrast, the residual tumors after neoadjuvant therapy showed a dramatic increase in the relative frequency of PIK3CA-mutant cells and a less pronounced decrease in the fraction of cells with HER2 amplification (Fig. 3a and Supplementary Figs. 7 and 8a,b ). These results demonstrate that cells with PIK3CA mutation exist in HER2-positive tumors before therapy but represent a minor population. The high sensitivity of STAR-FISH is reflected in our ability to detect these cells in almost all (20/22) of the untreated biopsy samples. In The Cancer Genome Atlas (TCGA) breast cancer study 12 , PIK3CA mutation encoding p.His1047Arg was only detected in 17% of HER2-positive tumors. This seeming discrepancy can be explained by the fact that, in 17 of 22 (77.3%) cases, the cells with PIK3CA mutation npg t e c h n i c a l r e p o r t s encoding p.His1047Arg constituted less than 5% of all cells in the tumor and therefore would not be detected by bulk tumor sequencing at the depths of coverage attained in the TCGA breast cancer study. To validate our STAR-FISH results by an independent, highly sensitive mutation detection method, we performed droplet digital PCR 26,27 using DNA extracted from formalin-fixed, paraffin-embedded slides adjacent to the ones used for STAR-FISH ( Supplementary Fig. 9a-d and Supplementary Note). PIK3CA-mutant cell detection with the two methods was highly concordant for samples with more than 20% tumor cell content (linear regression y = 0.6835x, P < 0.0001; correlation R 2 = 0.901, P = 0.0003). These results confirm that STAR-FISH allows for the detection of rare mutant cells with high specificity (FDR = 0.001), which is critical for the identification of probable resistance-conferring mechanisms.
Our single-cell analysis of the frequency of cells with HER2 amplification by STAR-FISH found substantial heterogeneity and changes due to treatment, in line with the results of previous studies [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . In pretreatment samples, only 32.5 ± 18% of all cells contained HER2 amplification, and this frequency decreased to an average of 23.5 ± 23.4% after neoadjuvant therapy, with considerable variation among patients. Assuming that the heterogeneity of the primary tumor is reflective of that of the disseminated cancer cells targeted by adjuvant therapy, the decrease in the frequency of HER2-amplified cells after neoadjuvant therapy may contribute to the suboptimal efficacy of HER2-targeted therapies in some patients. Our results also imply that it would be beneficial to reevaluate tumors after recurrence and design subsequent therapies on the basis of the resulting knowledge.
Changes in intratumoral heterogeneity after chemotherapy
Neoadjuvant chemotherapy appears to enrich for PIK3CA-mutant cells, potentially increasing the risk of resistance to subsequent HER2-targeted adjuvant therapies, conferred by the PIK3CA mutation but also by enrichment for cells lacking the HER2 amplicon. Analysis of each individual tumor area (Fig. 3b) showed an overall increase in the diversity of cellular subpopulations, as the majority of treatment-naive samples were composed of only three cell populations whereas post-treatment tumors often contained all five cell types ( Supplementary Figs. 7 and 8a) . Moreover, in many samples, there was also substantial variation among different areas of the same tumor, and this variance increased in many cases after chemotherapy (Supplementary Fig. 7 ). These results demonstrate that neoadjuvant chemotherapy changes the relative frequencies of genetically distinct cell populations in treatment-resistant residual tumors and suggest that some of these changes may have an unfavorable impact on the efficacy of subsequent adjuvant HER2-targeted therapies.
To further investigate global changes in intratumoral cellular genetic heterogeneity for PIK3CA and HER2, we calculated Shannon and Simpson's indices 40 in each sample before and after neoadjuvant treatment. These diversity measures allow for the characterization of each sample by a single value that reflects the relative abundance of cells in each of the five categories. The diversity index was significantly different between samples before and after treatment ( Fig. 3c and Supplementary Fig. 8c,d ). This significant (P = 0.014) shift in diversity was also present when we compared different areas of the same tumor (Fig. 3d) . These results imply that neoadjuvant treatment influences intratumoral cellular genetic diversity, not only as a result of changes in the frequencies of cell populations but also by increasing regional heterogeneity within tumors. 8   12  15  3  11  7  9  4  8  14  2  1   17  18  10  19  20  21  6  13  22  5  16   12  15  3  11  7  9  4  8  14  2  1  17  18  10  19  20  21  6  13 
and across areas (f). Patients are grouped on the basis of changes in diversity after treatment. **P = 0.0178, *P = 0.0596; NS, (not significant) P = 0.359. P values were calculated by log-rank test. Fig. 10 ). However, a larger number of samples will be necessary to demonstrate the generality of this finding.
Because PIK3CA mutations are thought to be associated with treatment resistance in HER2-positive tumors [15] [16] [17] [18] [19] and the changes in intratumoral diversity were in part due to variations in the fraction of PIK3CA-mutant cells, we analyzed potential associations between changes in diversity and patient outcome. Interestingly, the difference in cellular diversity between samples before and after neoadjuvant chemotherapy did not affect disease-free survival following adjuvant treatment with trastuzumab (Fig. 3e) . Similarly, changes in the fraction of PIK3CA-mutant cells were not by themselves predictive of recurrence (data not shown). However, when the diversity index was calculated on the basis of the cell type frequencies across different areas of the same tumor, a significant change in diversity was associated with shorter disease-free survival (Fig. 3f) . Because long-term survival is largely defined by progression to metastatic disease, our results imply a potential role for regional differences in the primary tumor microenvironment in selecting for treatmentresistant cancer cells capable of migration and metastatic dissemination. Surprisingly, both an increase and a decrease in the diversity of cell populations across different areas of the same tumor were associated with shorter disease-free survival (the decrease in diversity did not reach significance, likely owing to the low sample number, n = 2). Both patients showing a decrease in diversity across tumor areas after treatment received trastuzumab, a HER2-targeting therapy, in the neoadjuvant setting in addition to receiving it in the adjuvant setting ( Supplementary Fig. 4) . Cell type frequency plots in patients treated with neoadjuvant chemotherapy and trastuzumab (patients 20, 21 and 22) showed that the decrease in post-treatment diversity was due to the high similarity among the areas tested, with all five cell types present in similar proportions. Thus, including trastuzumab in neoadjuvant treatment seems to promote spatial homogeneity, but it does not prevent an increase in post-treatment cellular heterogeneity in patients who do not achieve a complete pathological response. Taken together, these results demonstrate that heterogeneity within primary tumors is an important determinant of long-term clinical outcome and that therapeutic resistance may be associated with changes both in cellular genetic and regional heterogeneity. These results also highlight the need to analyze tumors at the single-cell level in situ and the high clinical value of assessing primary tumors before and after neoadjuvant therapy and designing follow-up therapies on the basis of the resulting knowledge.
Co-occurrence of PIK3CA mutation and HER2 amplification STAR-FISH allows for the detection of genetic alterations in single cells and thus can be used to investigate the co-occurrence of two or more genetic events. The frequency of cells with single or combined genetic alterations can be used to predict the relative order of these changes to decipher the probable course of tumor evolution 41 . Thus, we used our STAR-FISH data to explore the relative order of HER2 amplification and PIK3CA mutation. If the two genetic events arise independently, then the probability of having both events present in the same cell is equal to the product of the probabilities for each individual event (see the Online Methods for details). Thus, if co-occurrence is favored, the probability of having both events is higher than expected by chance. We found that the observed frequency of co-occurrence for PIK3CA mutation and HER2 amplification in the same cell was higher than expected in the samples both before and after treatment (Fig. 4a) , implying higher fitness for cells with both alterations in comparison to cells with each individually. Co-occurrence of the PIK3CA mutation encoding p.His1047Arg with HER2 amplification within the same tumor has previously been reported 12, 39 . However, whether these two genetic alterations are in the same cancer cell or in different subpopulations has not been defined conclusively. Our results indicate that most cells with PIK3CA mutation encoding p.His1047Arg do not have HER2 amplification. Yet, the frequency of cells with both genetic events is significantly (P = 3.02 × 10 -6 ) higher than expected by chance. These results suggest that PIK3CA mutation encoding p.His1047Arg and HER2 amplification are independent genetic events and that cells with both events have a fitness advantage over others. Our results are in line with data in animal models, which show that the combination of PIK3CA mutation encoding p.His1047Arg with HER2 amplification accelerates tumor formation and metastatic progression and confers resistance to HER2-targeted therapies 42 .
Model of the relative order of genetic events
Next, we examined the relative order of PIK3CA mutation and HER2 amplification during tumor progression. To determine the time during tumor progression at which these genetic events arose, a mathematical model was constructed on the basis of STAR-FISH-derived numbers of cells with PIK3CA mutation and with HER2 amplification and the cell death and proliferation rates of cells with these genetic alterations, Figure 4 Probable course of tumor evolution based on the co-occurrence of PIK3CA mutation and HER2 amplification. (a) Co-occurrence of PIK3CA mutation encoding p.His1047Arg and HER2 amplification in the same cell. The expected probability (P exp ) of co-occurrence of the two genetic events is compared with the observed probability (P obs ) based on the frequency of MUT + AMP cells. Error bars, s.d. of the expected or observed values divided by the square root of the total number of samples.
(b) Mathematical model of probable tumor evolution with prediction of the time at which each event arises (t HER2 and t H1047R ), based on STAR-FISH counts for both events (crosses) at the observation time (t end ) and the net growth rates attributed to these events on the basis of published data 42 .
npg t e c h n i c a l r e p o r t s individually and in combination, in a transgenic model of HER2-positive breast cancer 42 , assuming that the characteristics of human and mouse mammary tumor cells with PIK3CA mutation encoding p.His1047Arg and HER2 amplification are similar (see the Online Methods for details). This model suggested that HER2 amplification arises first and that PIK3CA mutation is acquired at later stages of tumor progression (Fig. 4b) . Although with the current data it is not possible to predict whether the observed diversity for PIK3CA mutation and HER2 amplification is a result of the parallel evolution of two independent cell populations or diversification at a later stage, our mathematical modeling of the temporal order of events supports the notion that HER2 amplification is an early event in breast tumor evolution.
Spatial distribution of genetically distinct subpopulations
Our data showing associations between intratumoral diversity across different areas of the same tumor and long-term clinical outcome (Fig. 3f) raised the possibility of local microenvironments within primary tumors favoring the expansion of genetically distinct cell populations. To investigate this possibility further, we asked whether different cell types within the tumor were distributed randomly or there was any spatial clustering of cell types. Although we found no significant correlation of the presence of any two individual cell types in the same sample, there was a trend for the co-occurrence of cells with PIK3CA mutation alone (MUT) and cells with both PIK3CA mutation and HER2 amplification (MUT +AMP) (Fig. 5a) .
To further investigate potential relationships between the intratumoral localizations of different cell types, we performed spatial distribution analyses. Kernel density and counts of cell type densities were calculated for each cell type ( Fig. 5b; see the Online Methods for details). These measurements were used to assess whether cells of a certain type tended to cluster together or be randomly distributed across the investigated area. k-means clustering 43 showed that cells with PIK3CA mutation, irrespectively of their HER2 amplification status, tended to form clusters in situ (Fig. 5b) . Cells with wild-type PIK3CA and no HER2 amplification had the lowest clustering score, and this remained unchanged after treatment (Fig. 5c) . Neoadjuvant therapy seemed to have opposing effects on MUT and MUT + AMP cells in comparison to WT and WT + AMP cells: for cells with PIK3CA mutation, the clustering score after treatment was decreased to the level of WT cells (cells were more dispersed after treatment), whereas for AMP and WT + AMP cells the clustering score was increased (cells were less dispersed after treatment). These results suggest that WT cells are most likely non-malignant stromal cells, as their distribution Formation of larger clusters in two-dimensional space is indicated by an increase in clustering score, the ratio of between-and within-cluster variation in kernel means: a higher ratio means more clustering, whereas a lower ratio signifies a more random distribution.
npg t e c h n i c a l r e p o r t s within tumors neither showed any specific pattern nor was affected by treatment. In contrast, the increased dispersion of cancer cells with PIK3CA mutation after treatment implies that these cells might be more migratory. Indeed, PIK3CA mutations were shown to increase cell motility 42, 44 , supporting our hypothesis.
DISCUSSION
The STAR-FISH method we describe here is relatively inexpensive and the results are easy to interpret. It is also much more sensitive than sequencing or mass spectrometry-based 45 methods, as even a single mutant cell can be detected among thousands of cells analyzed with FDR = 0.001. Other methods, such as padlock-probe rolling-circle amplification, can be used to detect mutations in situ on the basis of mRNA 46 . However, mRNA levels can be affected by tissue handling, the nature of the mutation (for example, some result in nonsensemediated decay 47 ) and cancer treatment. Thus, methods based on DNA detection such as STAR-FISH are more suited for clinical studies; STAR-FISH in particular is useful for these studies because it utilizes standard formalin-fixed, paraffin-embedded samples that are routinely available. Because intratumoral heterogeneity is one of the main drivers of disease progression and therapy resistance, including STAR-FISH analysis in clinical practice could improve patient stratification and the design of optimal individualized therapies. Owing to its high sensitivity and specificity in detecting mutant cells, STAR-FISH could especially be useful for guiding the design of targeted therapies with known genetic resistance mechanisms. The limitations of STAR-FISH include the need for a priori knowledge of the mutation to be analyzed and the number of fluorophores that can be applied to detect in situ PCR products and chromosomal regions. The ability to increase multiplexing by combining STAR-FISH with other detection methods such as FISSEQ 48 or CyTOF-based approaches 49 can transform this novel method into an exceptionally powerful diagnostic pathology assay for single-cell mutation detection and genetic heterogeneity analysis. In summary, we applied a novel in situ technique to assess the clinical impact of changes in intratumoral heterogeneity during neoadjuvant therapy. STAR-FISH detected mutant cells with high sensitivity and did so in intact tissues, enabling mapping of the spatial distribution of subpopulations of cancer cells. Our results show that chemotherapy affects both the frequency and topology of these subpopulations. Changes in diversity across different areas of the same tumor proved to be more significant clinically than changes in overall diversity. This finding suggests that the application of in situ techniques might be key for the design of more effective therapies for heterogeneous tumors.
METHODS
Methods and any associated references are available in the online version of the paper. Xenograft assays. All animal procedures were approved by the Dana-Farber Cancer Institute Animal Care and Use Committee (ACUC) and followed US National Institutes of Health guidelines. Bilateral mammary fat pad injection of 1 × 10 6 cells resuspended in 50% Matrigel (BD Biosciences) per transplant were performed on 4-to 5-week-old female NCRNU-F mice (Taconic). Tumor volumes were monitored by biweekly caliper measurements until a volume of 1.2 cm 3 was reached. Tumors were then excised and processed into formalinfixed, paraffin-embedded blocks. For xenograft assays with mixed cell lines, MDA-MB-231 and SUM-185PE cells expressing mCherry and GFP, respectively, were generated by lentiviral infection, as previously described 52 . Cells were collected, mixed at different ratios (total cell number of 2 × 10 6 ), mixed with 50% Matrigel and injected into the mammary fat pad of NCRNU-F mice. Tumors were removed when they reached 1 cm in diameter and cut into two equal pieces-one for formalin-fixed, paraffin-embedded processing and one for FACS analysis.
FACS for GFP-and mCherry-labeled cells. Tumor tissue was digested with 2 mg/ml collageanse I (Worthington Biochemical Corporation) and 2 mg/ml hyaluronidase (Sigma-Aldrich). Following dissociation, the sample was passed through a 40-µm cell strainer (BD Biosciences), washed in PBS with 0.5 mM EDTA and 5% BSA, and analyzed on a BD LSRFortessa analyzer. The gating for forward scatter and side scatter was set to exclude dead cells and doublets.
Immunofluorescence analyses. After deparaffininzation and rehydration, slides were subjected to antigen retrieval in citrate buffer (pH 6; Dako) for 20 min in a steamer. Blocking solution (10% FCS in PBST) was applied for 10 min. Incubation with primary antibody in PBS was held overnight at 4 °C in a moist chamber. Secondary antibody was applied for 45 min at room temperature. Samples were mounted with VectaShield HardSet Antifade Mounting Medium with DAPI (Vector Laboratories). Imaging was performed on a Leica SP5 confocal microscope. The antibodies used 52 included monoclonal antibody to GFP (sc-9996, mouse monoclonal IgG2a, Santa Cruz Biotechnology; 1:50 dilution), goat antibody to rabbit conjugated to Alexa Fluor 488 (Life Technologies; 1:100 dilution) and mouse monoclonal antibody to SMA (M085101, clone 1A4, mouse monoclonal IgG2a, Dako; 1:250 dilution).
STAR-FISH in situ PCR conditions. The first round of in situ PCR for the PIK3CA mutation encoding p.His1047Arg was performed with 2 mM MgCl 2 , 200 µM dNTPs, 250 nM primers (for primer design, see the Supplementary Note) and 0.1 U/µl Platinum Taq Polymerase (Life Technologies) in 10× Platinum Taq Buffer (without MgCl 2 ; Life Technologies). A total of nine cycles were performed, in three steps of three cycles each with annealing temperatures at 45 °C, 52 °C and 58 °C. All cycling steps were 30 s long. The second round of PCR for the PIK3CA mutation encoding p.His1047Arg was performed with 3.5 mM MgCl 2 , 200 µM dNTPs, 250 nM primers and 0.1 U/µl Platinum Taq Polymerase in 10× Platinum Taq Buffer (without MgCl 2 ). A total of 30 cycles were performed, 5 cycles with the annealing temperature at 45 °C, 5 cycles with the annealing temperature at 52 °C and 20 cycles with the annealing temperature at 58 °C. All cycling steps were 30 s long. The first round of PCR for the PIK3CA mutation encoding p.Glu542Lys was performed with 4 mM MgCl 2 , 150 µM dNTPs, 250 nM primers and 0.1 U/µl Platinum Taq Polymerase in 10× Platinum Taq Buffer (without MgCl 2 ). A total of nine cycles were performed, with the annealing temperature at 56 °C; the cycling steps were 30 s long. The second round of PCR for the PIK3CA mutation encoding p.Glu542Lys was performed as for the PIK3CA mutation encoding p.His1047Arg, with 4 mM MgCl 2 and 150 µM dNTPs. For the TP53 mutation encoding p.Arg175His, 2 mM MgCl 2 and 200 µM dNTPs were used in both PCR rounds. Because the amplicon resides in a GC-rich region, deoxy-7-deazaguanosine triphosphate (dc 7 GTP) was added and a slowdown PCR program was used, as described before 53 . The second round of PCR was performed as for the PIK3CA mutation encoding p.His1047Arg.
STAR-FISH.
Formalin-fixed, paraffin-embedded tissue sections (5 µm thick) on silylated glass slides were baked overnight at 70 °C, dewaxed in xylene (Leica Microsystems), washed in 100%, 70% and 50% ethanol (Leica Microsystems), rinsed with water and air dried for 1 h. After baking at 105 °C for 2 min, the samples were treated with 20 µg/ml proteinase K in PBS (Ambion) at 37 °C for 12 min (xenografts) or 18-20 min (human tumors). To increase the signal-to-noise ratio, the slides were then rinsed in water and treated with 100 µg/ml RNase in 2× SSC buffer (Fisher Scientific) for 1 h at 37 °C. Next, a 5-min wash in 5% Chelex beads (Bio-Rad) in water with agitation was applied and followed by two more washes with water. Excess water was drained, frame-seal incubation chambers (Bio-Rad) were applied to the slides, the master mix for the first round of PCR was pipetted on top of the tissue, the chambers were sealed and the slides were placed in the in situ PCR machine (Bio-Rad DNA Engine with Slide Tower). The first round of PCR was run for nine cycles. The frames were removed, excess remaining reagents were drained and new frames were applied before the addition of the master mix for the second round of PCR. The second round of PCR was run for 30 cycles. After removal of the frames, the slides were washed in water, dehydrated in increasing concentrations of ethanol (50%, 70%, 85% and 100%) and air dried. FISH probe mix, containing custom-designed probes recognizing wild-type and mutant PCR products (labeled with dFluorescein and TYE, respectively; Exiqon), HER2 BAC probe (RP11-94L15; kindly provided by H. Russness and I. Rye; labeled with Spectrum Orange dUTP by Nick-Translation kit (Abbott Molecular)) and CEP17Aqua probe (Abbott Molecular), was then added to the slides, and coverslips were applied and sealed with rubber cement. Hybridization was performed for 7 min at 75 °C followed by overnight incubation at 37 °C in a humid chamber. The slides were then washed in 0.4× SSC with 0.3% NP-40 for 2 min at room temperature and 0.4× SSC with 0.3% NP-40 for 2 min at 74 °C followed by rinses in 2× SSC with 0.1% NP-40, 2× SSC and PBS. Nuclear counterstaining was performed by incubation for 10 min at room temperature with 1 µM To-Pro-3 in PBS (Molecular Probes, Life Technologies). After two additional washes in PBS and one wash in water, the slides were dried and mounted with VectaShield Mounting Medium (Vector Laboratories), covered with coverslips and stored overnight to 3 d at −20 °C.
Image acquisition and quantification of STAR-FISH signal. STAR-FISH images were acquired in z stacks (0.25 µm thick per slice, average of seven slices per image) with a Leica SP5X laser-scanning confocal microscope with a white-light laser and 63× Plan Apo objective. Image resolution was set at 1,024 × 1,024 pixels, and the scanning speed was set at 400 Hz. All images were acquired in sequential mode to avoid fluorophore crosstalk. For each sample, 3-5 images of different regions were collected to account for intratumoral npg cells to the following values: 0.5, 0.55, …, 0.9, in increments of 0.05. We found that the model using any of these values predicted that HER2 amplification was the first event. Second, we changed the death rate for HER2-amplified cells to the following values: 0.06, 0.10, 0.14, 0.18 and 0.22. Similarly, we found that HER2 amplification was the first event in all these scenarios. Thus, we conclude that HER2 amplification is very likely the first event, followed by PIK3CA mutation, even taking into account the uncertainty in parameter estimation and differences in estimates between human and mouse cells. To perform a more detailed analysis of the evolutionary dynamics of the acquisition of these mutations, additional data from human cells are necessary.
Spatial analyses. We then sought to determine whether there was any spatial clustering of the cell types within samples. For each sample, we obtained a 1,024 × 1,024 pixel square image to display the spatial distribution of each measured cell. For each sample and each mutation type, we performed k-means clustering 43 with k = 3. We then calculated the ratio of between-cluster sums of squares versus the total sums of squares to quantify the randomness in localization for each mutation species. When this ratio is larger, k = 3 is sufficient to cluster the spatial data, whereas when this ratio is lower the spatial data might form smaller clusters and k = 3 is insufficient, with cells more sporadically distributed. Finally, we used the Wilcoxon rank-sum test to determine whether there was any significant difference in the distribution of this ratio between pretreatment and post-treatment samples.
